Abstract

CLC Number:

R737.9

石媛媛, 赵杨, 刘赛璇, 申兴斌. STAT1在乳腺癌中作用机制的研究进展[J]. 承德医学院学报, 2024, 41(1): 57-61.

[1] Herrera SC, Bach EA. JAK/STAT signaling in stem cells and regeneration: from Drosophila to vertebrates[J]. Development, 2019, 146(2): dev167643.
[2] Tian X, Guan W, Zhang L, et al.Physical interaction of STAT1 isoforms with TGF-β receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer[J]. J Exp Clin Cancer Res, 2018, 37(1): 103.
[3] 黄平,窦长武,鞠海涛,等. STAT1与恶性肿瘤关系的研究进展[J]. 临床神经外科杂志,2015,12(4):314-316.
[4] 吴春丽,张顺,蔡挺. PIAS1与肿瘤[J]. 中国生物化学与分子生物学报,2017,33(5):423-428.
[5] Hin Tang JJ, Hao Thng DK, Lim JJ, et al. JAK/STAT signaling in hepatocellular carcinoma[J]. Hepat Oncol, 2020, 7(1): HEP18.
[6] Chen J, Zhao J, Chen L, et al.STAT1 modification improves therapeutic effects of interferons on lung cancer cells[J]. J Transl Med, 2015, 13: 293.
[7] 孙宁,孙宇,张宝帅,等. 沉默/增强Stat1 对胰腺癌细胞增殖和迁移的影响[J]. 基础医学与临床,2017,37(6):845-848.
[8] Liu Z, Zhang Y, Chen Y, et al.STAT1 inhibits STAT3 activation in esophageal squamous cell carcinoma[J]. Cancer Manag Res, 2018, 10: 6517-6523.
[9] 陈鲤群,刘国娟. STAT1 与肿瘤关系的研究进展与展望[J]. 中国细胞生物学学报,2017,39(12):1612-1618.
[10] 黄盼盼. PLSCR1 激活STAT1 信号通路促进基底样乳腺癌的发生发展[D]. 杭州:浙江大学,2020.
[11] Liu LC, Su CH, Wang HC, et al.Contribution of personalized Cyclin D1 genotype to triple negative breast cancer risk[J]. Biomedicine (Taipei), 2014, 4(1): 3.
[12] Gonzalez-perez RR, Lanier V, Newman G. Leptin's Pro-Angiogenic Signature in Breast Cancer[J]. Cancers (Basel), 2013, 5(3): 1140-1162.
[13] Moore N, Houghton J, Lyle S.Slow-cycling therapy-resistant cancer cells[J]. Stem Cells Dev, 2012, 21(10): 1822-1830.
[14] Tymoszuk P, Charoentong P, Hackl H, et al.High STAT1 mRNA levels but not its tyrosine phosphorylation are associated with macrophage infiltration and bad prognosis in breast cancer[J]. BMC Cancer, 2014, 14: 257.
[15] Schlee M, Hölzel M, Bernard S, et al.C-myc activation impairs the NF-kappaB and the interferon response: implications for the pathogenesis of Burkitt's lymphoma[J]. Int J Cancer, 2007, 120(7): 1387-1395.
[16] Nakayama Y, Mimura K, Tamaki T, et al.Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer[J]. Int J Oncol, 2019, 54(6): 2030-2038.
[17] Kumar A, Commane M, Flickinger TW, et al.Defective TNF-alpha-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases[J]. Science, 1997, 278(5343): 1630-1632.
[18] 杨宏坤. 乳腺癌中STAT1 的表达及其生物信息学分析和生物学功能的实验研究[D]. 包头:内蒙古医科大学, 2021.
[19] Nair VS, Toor SM, Ali BR, et al.Dual inhibition of STAT1 and STAT3 activation downregulates expression of PD-L1 in human breast cancer cells[J]. Expert Opin Ther Targets, 2018, 22(6): 547-557.
[20] Movahedi K, Guilliams M, Van Den Bossche J, et al. Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity[J]. Blood, 2008, 111(8): 4233-4244.
[21] Zhang M.Novel function of STAT1 in breast cancer[J]. Oncoimmunology, 2013, 2(8): e25125.
[22] Lesinski GB, Anghelina M, Zimmerer J, et al.The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse[J]. J Clin Invest, 2003, 112(2): 170-180.
[23] Timofeeva OA, Plisov S, Evseev AA, et al.Serine-phosphorylated STAT1 is a prosurvival factor in Wilms' tumor pathogenesis[J]. Oncogene, 2006, 25(58): 7555-7564.
[24] Koromilas AE, Sexl V.The tumor suppressor function of STAT1 in breast cancer[J]. Jakstat, 2013, 2(2): e23353.
[25] Klover PJ, Muller WJ, Robinson GW, et al.Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden[J]. Neoplasia, 2010, 12(11): 899-905.
[26] Raven JF, Williams V, Wang S, et al.Stat1 is a suppressor of ErbB2/Neu-mediated cellular transformation and mouse mammary gland tumor formation[J]. Cell Cycle, 2011, 10(5): 794-804.
[27] 刘雨欣. 信号传导和转录激活因子1在乳腺癌组织的表达及与预后的关系[D]. 长春:吉林大学,2016.
[28] 梁晶,贾新凤,韩福才.肺癌患者外周血中MMP-7mRNA、sMICA、VEGF 的表达及其与侵袭转移的关系[J]. 肿瘤防治研究,2016,43(6):508-512.
[29] Ma J, Chen J, Wang H, et al.AhR regulates VEGF expression by promoting STAT1 transcriptional activity, thereby affecting endothelial angiogenesis in acute limb ischemia[J]. Chem Biol Interact, 2023, 369: 110253.
[30] Suyun H, Bucana CD, Melissa VA, et al.Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells[J]. Oncogene, 2002, 21(16):2504-2512.
[31] Arseni L, Lanzafame M, Compe E, et al.TFIIH-dependent MMP-1 overexpression in trichothiodystrophy leads to extracellular matrix alterations in patient skin[J]. Proc Natl Acad Sci USA, 2015,112(5): 1499-1504.
[32] Gujam FJ, Mcmillan DC, Edwards J.The relationship between total and phosphorylated STAT1 and STAT3 tumour cell expression, components of tumour microenvironment and survival in patients with invasive ductal breast cancer[J]. Oncotarget, 2016, 7(47): 77607-77621.
[33] Avalle L, Pensa S, Regis G, et al.STAT1 and STAT3 in tumorigenesis: A matter of balance[J]. Jakstat, 2012, 1(2): 65-72.
[34] Turkson J, Jove R.STAT proteins: novel molecular targets for cancer drug discovery[J]. Oncogene, 2000, 19(56): 6613-6626.
[35] Magkou C, Giannopoulou I, Theohari I, et al.Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer[J]. Histopathology, 2012, 60(7): 1125-1132.
[36] Meissl K, Macho-maschler S, Müller M, et al. The good and the bad faces of STAT1 in solid tumours[J]. Cytokine, 2017, 89: 12-20.

STAT1在乳腺癌中作用机制的研究进展

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	WANG Wei-si, GUO Shi-gang, LI Guo-ming, FU Xin-ao, LI Ju-shang, FAN Zong-qi. Expression of Androgen Receptor and Ki-67 in Triple-negative Breast Cancer and Its Association with Prognosis [J]. Journal of Chengde Medical University, 2024, 41(1): 15-20.
[2]	. [J]. Journal of Chengde Medical University, 2023, 40(4): 329-333.
[3]	LIU A-min, ZHAO Wen-bin, CHEN Bao-ping. Over-expression of Circular RNA-103809 Regulating Oxidative Stress and Immunity of Breast Cancer Cells [J]. Journal of Chengde Medical University, 2022, 39(6): 455-460.
[4]	. [J]. Journal of Chengde Medical University, 2022, 39(2): 159-162.
[5]	. [J]. Journal of Chengde Medical University, 2021, 38(6): 513-517.
[6]	LI Lu, HUANG Yan-jie, ZHENG Ji-ning. Meta Analysis of the Correlation between the Expression of mTOR, p-mTOR and Colorectal Cancer [J]. Journal of Chengde Medical University, 2021, 38(5): 365-370.
[7]	GUAN Jian-hua, ZHANG Jun-lin, TAN Yin-huan, LI Wei-wen, LIN Qi-mou. Application of Daytime Operation in Breast Benign Tumor Resection in Jiangmen Wuyi District [J]. Journal of Chengde Medical University, 2020, 37(6): 465-468.
[8]	. [J]. Journal of Chengde Medical University, 2020, 37(6): 505-507.
[9]	NIU Lin, LIU Lei, CHENG Lu-yang, XU Qian, CHEN Zhi-hong, QIAO Yue-bing. Screening Key Genes and Pathways in Triple-negative Breast Cancer by Bioinformatics Analysis [J]. Journal of Chengde Medical University, 2020, 37(5): 361-368.
[10]	WEI Dong. Clinical Study on the Treatment of Simple Breast Cysts with Ultrasound-guided Tapping and Hypertonic Glucose Injection [J]. Journal of Chengde Medical University, 2020, 37(5): 381-384.
[11]	. [J]. Journal of Chengde Medical University, 2020, 37(5): 410-414.
[12]	. [J]. Journal of Chengde Medical University, 2018, 35(3): 252-253.
[13]	XUE Jing, ZHAO Yang, CHENG Yu, et al. EXPRESSION AND CLINICAL SIGNIFICANCE OF IGF-1 IN HUMAN BREAST CANCER [J]. Journal of Chengde Medical University, 2018, 35(2): 99-101.
[14]	. [J]. Journal of Chengde Medical University, 2018, 35(1): 32-34.
[15]	. [J]. Journal of Chengde Medical University, 2017, 34(4): 347-348.